Start a Buy-and-Bill Bridge-Lending Product for Infusion Centers

1. 1

   Understand the gap you are underwriting

   The infusion center buys an expensive drug, administers it, and waits 30 to 60 days for a relatively predictable reimbursement. You are financing that gap: advancing against a receivable that is likely but not guaranteed to be paid. Understand the reimbursement, denial, and white-bagging risks precisely, because they determine your underwriting. This specific, definable risk is what makes the lending possible.

2. 2

   Assemble capital and underwriting expertise

   You need lending capital (your own, a fund, or a credit facility) and the healthcare-reimbursement expertise to underwrite which purchases and which centers are good risks. The rare combination of finance and reimbursement knowledge is your edge. Generalist lenders that do not understand buy-and-bill cannot price this well.

3. 3

   Build the product and risk controls

   Design the financing (a revolving line, per-purchase advances, or a corporate-card-linked product), with underwriting on the center's payer mix, denial history, and drug portfolio. Build controls for denials, biosimilar repricing, and white-bagging, which are the ways the receivable can shrink or vanish. Sound risk controls protect your capital and your business.

4. 4

   Address the licensing and regulatory reality

   Commercial lending and any fintech or card product carry licensing and regulatory obligations that vary by structure and state, so get financial-services counsel to structure the product compliantly. This is regulated financial activity, not just software. Compliance is foundational, not optional.

5. 5

   Lend to centers and grow with the sector

   Your customers are infusion centers and platforms starved for working capital as they grow. Price the interest and fees to the risk, and grow your book as the infusion sector expands. A lender that understands buy-and-bill better than anyone can become the default financing partner for a growing niche.

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.

Best for: Specialty-finance and fintech operators who understand healthcare reimbursement risk

Not for: Not for a founder who wants to automate the reconciliation rather than lend the capital; that is the AI buy-and-bill financial-automation card, though the two combine well. Not for a generalist lender unwilling to master reimbursement risk. And not for anyone without the capital or the appetite for regulated lending.